CLEAN : France at odds with

The video discusses the struggle to secure medical rights and evaluates the necessity of third-generation contraceptive pills. Experts unanimously agree that these pills offer no advantage over second-generation ones, leading to recommendations against their reimbursement and limiting their use to second-intention prescriptions. The influence of pharmaceutical companies in promoting these pills is highlighted. The video concludes with a call for regulatory actions to restrict market authorization of third and fourth-generation pills to second-intention use.

What is the main focus of the initial discussion regarding medication evaluation?

• The effectiveness of third-generation pills

• The role of pharmaceutical companies

• The right to evaluate medications closely related to health

• The cost of medications

What is the expert consensus on the use of third-generation pills compared to second-generation ones?

• Third-generation pills are more effective

• Third-generation pills are cheaper

• Second-generation pills should be discontinued

• There is no additional benefit in using third-generation pills

Why is it suggested to limit the prescription of third-generation pills?

• They have more side effects

• They are more expensive

• They are not available in all regions

• They should be used only as a second intention

What efforts have pharmaceutical companies made regarding new medications?

• They have promoted and highlighted the benefits of new medications

• They have stopped producing older medications

• They have collaborated with health agencies

• They have reduced prices

What action is requested from the national agency concerning third and fourth-generation pills?

• To reduce their prices

• To promote their use

• To seek European restrictions on their market authorization

• To increase their market availability